Curis | CRIS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bayer EUR 5.35B 1.02B 2025-09
Bristol-Myers Squibb USD 8.79B 110M 2025-09
CSL USD 4.46B 2.71B 2025-12
Curis USD -7.72M 140K 2024-06
Eli Lilly USD 14.59B 1.48B 2025-09
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Incyte USD 1.39B 118.68M 2025-12
Merck USD 13.42B 431M 2025-09
Novartis USD 10.25B 570M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Takeda JPY 790.55B 262.97B 2025-12
TG Therapeutics USD 154.43M 20.81M 2025-12
Verastem USD 545K 543K 2021-12
Xoma 992K 846K 2024-06